Cello Health Dividends - CLL

Cello Health Dividends - CLL

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Cello Health Plc CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  0.00 0.0% 127.50 127.50 127.50 127.50 127.50 08:00:00
more quote information »
Industry Sector
MEDIA

Cello Health CLL Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
21/03/2019FinalGBX2.7531/12/201731/12/201825/04/201926/04/201924/05/20193.85
19/09/2018InterimGBX1.131/12/201731/12/201804/10/201805/10/201802/11/20180
22/03/2018FinalGBX2.4531/12/201631/12/201703/05/201804/05/201825/05/20183.5
20/09/2017InterimGBX1.0531/12/201631/12/201705/10/201706/10/201703/11/20170
22/03/2017FinalGBX2.431/12/201531/12/201604/05/201705/05/201726/05/20173.4
14/09/2016InterimGBX131/12/201531/12/201606/10/201607/10/201604/11/20160
17/03/2016FinalGBX2.0231/12/201431/12/201505/05/201606/05/201627/05/20162.86
16/09/2015InterimGBX0.8431/12/201431/12/201521/10/201522/10/201527/11/20150
19/03/2015FinalGBX1.831/12/201331/12/201430/04/201501/05/201529/05/20152.6
17/09/2014InterimGBX0.831/12/201331/12/201401/10/201403/10/201407/11/20140
20/03/2014FinalGBX1.6131/12/201231/12/201304/06/201406/06/201404/07/20142.25
18/09/2013InterimGBX0.6431/12/201231/12/201304/12/201306/12/201306/01/20140
13/03/2013FinalGBX1.4231/12/201131/12/201229/05/201331/05/201305/07/20132
19/09/2012InterimGBX0.5831/12/201131/12/201207/12/201209/12/201204/01/20130
13/03/2012FinalGBX1.1731/12/201031/12/201106/06/201208/06/201206/07/20121.72
13/09/2011InterimGBX0.5531/12/201031/12/201107/12/201109/12/201106/01/20120
15/03/2011FinalGBX0.931/12/200931/12/201008/06/201110/06/201108/07/20111.43
14/09/2010InterimGBX0.52531/12/200931/12/201006/10/201008/10/201003/11/20100
16/03/2010FinalGBX0.831/12/200831/12/200919/05/201021/05/201016/06/20101.3
15/09/2009InterimGBX0.530/06/200830/06/200907/10/200909/10/200904/11/20090
17/03/2009FinalGBX0.7531/12/200731/12/200820/05/200922/05/200917/06/20091.25
16/09/2008InterimGBX0.530/06/200730/06/200808/10/200810/10/200805/11/20080
23/03/2008FinalGBX0.7531/12/200631/12/200721/05/200823/05/200818/06/20081.2
20/03/2007FinalGBX0.631/12/200531/12/200623/05/200725/05/200715/06/20071
05/09/2006InterimGBX0.430/12/200530/06/200620/09/200622/09/200613/10/20060

Top Dividend Posts

DateSubject
21/3/2019
10:44
davebowler: Cenkos; Organic momentum continues Today’s largely in-line results were well flagged by January’s trading update, but there are notable beats on EPS, DPS and Net cash. The group continues its organically focused delivery, leveraging Signal’s digital capabilities into the healthcare space, alongside new office openings. This will continue Cello’s migration over time into a more healthcare-focused, US-centric and higher margin business. We feel the defensive nature and FCF potential of Cello are not fairly valued in the current share price.
08/2/2017
09:52
qs99: Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla
06/2/2017
12:06
davebowler: FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition.
01/2/2017
11:39
zipstuck: The oversubscribed placing underpins the share price and there is all to play for in 2017
19/1/2017
09:36
davebowler: Price: 100.0p Target Price: 132.0p finncap.com Cello has confirmed the Group delivered an encouraging trading performance in 2016 and 2017 begins with good momentum from existing and new clients. Most importantly for our buy case, there has been an ‘excellent performance’ from Cello’s growing suite of software-enabled products. We make no changes to our forecasts and continue to believe the share price significantly undervalues the technologies Cello has developed, most notably Pulsar its social media analytics tool which we believe is in the price for free.
28/9/2016
09:58
davebowler: Finncap; Price: 106.0p Target Price: 132p Cello has an overlooked and potentially significantly undervalued asset that is now out of development phase. Cello Pulsar is a social media analytics tool that has significant points of difference to the competition. In the right hands, social media data can inform, direct and optimise marketing campaigns but to date its usage has been constrained by early-stage science and customer unfamiliarity. Competitors in this area have individually raised nearly half of Cello's market cap, emphasising Pulsar’s potential to add very material value to the share price. We initiate at Buy.
03/6/2014
17:44
qs9: nice IMO to see directors taking advantage of recent share price weakness...
08/5/2013
14:58
hpcg: I think its a bit chicken and egg with regards to liquidity / spread; its thinly traded which puts people off. If they participated then there would be more liquidity! However I'm speculating as to the motives of others, and it could just be that investors want to see more prolonged evidence of progress. If the company does the business the share price will as well.
17/9/2010
21:17
stegrego: Hybridan Cello Group (CLL 46p/£28.25m) Cello continues its impressive share price performance with a further rise of over 25 per cent since the end of July when we last commented on the Company. Today it announced its half year results showing headline ongoing operating profit up 25 per cent to £3.3m (2009: £2.6m), margins improved to 10.9 per cent (2009: 8.9 per cent) and net debt down to £11.7m (2009: £14.8m). The fall off in income from the public sector has not impacted materially the overall mix of business, with the top 20 clients from 2009 remaining significant revenue generators for the Company in 2010, with many increasing their levels of expenditure. The largest customer accounts for only 4.4 per cent of total income, with the top 20 customers for less than 40 per cent. The robust Pharmaceutical sector on the other hand now accounts for over 25 percent of the group's income. The Company thus appears to have created a secure and solid base from which to advance. On the results the CEO commented "We are now seeing a pick up from our clients in the private sector across a range of industries....(and) have started to carefully organically expand the business again". This positive statement, along with the small 5 percent increase in the interim dividend bodes well for investors who we expect to continue to support the progress of this growing company.
01/4/2010
12:40
glasshalfull: Well I disagree GCI :-) I've been nibbling away and have bought a few CLL since results which I expect to represent the nadir of the share price underperformance. I had researched and was a holder of CLL back in 2006 and discovered that I still had a few (dormant account), so only recently got up to speed on developments since. My interest was rekindled having carried out comprehensive research on Adventis (ATG) a marketing services company - see link below - and I noticed that both ATG and CLL had failed to enjoy the shareprice recovery that many of their peers had. http://boards.fool.co.uk/Message.asp?mid=11859117 I've started a write-up on CLL and will post when complete. Regards GHF
Your Recent History
LSE
CLL
Cello Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 16:15:33